Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation

Author:

Shah Gunjan L.ORCID,DeWolf SusanORCID,Lee Yeon JooORCID,Tamari Roni,Dahi Parastoo B.ORCID,Lavery Jessica A.ORCID,Ruiz Josel,Devlin Sean M.,Cho Christina,Peled Jonathan U.ORCID,Politikos Ioannis,Scordo Michael,Babady N. Esther,Jain TaniaORCID,Vardhana SantoshaORCID,Daniyan Anthony,Sauter Craig S.,Barker Juliet N.ORCID,Giralt Sergio A.ORCID,Goss Cheryl,Maslak Peter,Hohl Tobias M.ORCID,Kamboj Mini,Ramanathan Lakshmi,van den Brink Marcel R.M.ORCID,Papadopoulos Esperanza,Papanicolaou Genovefa,Perales Miguel-AngelORCID

Funder

NIH, NCI

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference45 articles.

1. Johns Hopkins Coronavirus Resource Center. COVID-19 United States Cases by County. https://coronavirus.jhu.edu/us-map Accessed Jun 2, 2020

2. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak;Dai;Cancer Discov,2020

3. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent

4. A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells

5. Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3